Favourable Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Metastatic Rectal Neuroendocrine Neoplasia (NEN) Abstract #2182

Introduction: Metastatic disease from rectal NEN are less common than other NEN origins, and carries a poor prognosis. Treatment evidence for such patients (pts) is lacking.
Aim(s): We assessed PRRT outcomes in pts with somatostatin receptor (SSTR) positive metastatic rectal NEN from 2 referral centres.
Materials and methods: Pts treated with PRRT were retrospectively reviewed. Anatomical imaging (RECIST 1.1), SSTR imaging response and toxicity were assessed 3 months post-PRRT. Kaplan-Meier estimate was used to determine progression free survival (PFS) and overall survival (OS) from start of PRRT.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Grace Kong

To read results and conclusion, please login ...

Further abstracts you may be interested in

#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors
Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#688 Does Small Mean Benign? Not for the WHO 2010 Classification of Gastrointestinal Neuroendocrine Tumors (NETs): A Case Report of a Small Rectal Neuroendocrine Neoplasm (NEN) with Distant Metastatic Spread
Introduction: The gastrointestinal tract is the most common site of primary NETs, just over a quarter of which are rectal. According to the WHO 2000/2004 non-functioning NETs, ≤2cm with no muscularis propria or vascular invasion are classified as well differentiated (WD) NET with benign behavior. However, several case series report metastatic spread from NETs in this category. In 2010, a new WHO classification was introduced with the premise that all NETs were considered malignant with metastatic potential.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: Dr Tu Vinh Luong
#889 Delayed Haematological Toxicity in Patients Treated with 177Lu-octreotate Peptide Receptor Radiotherapy (PRRT) for Metastatic Neuroendocrine Tumors (NETs)
Introduction: PRRT is associated with a high tumor control rate and early toxicity seems acceptable (haematological grade 3-4 toxicity: 11.3%). Long-term monitoring of haematological toxicity is unavailable.
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Olivia Hentic
#1020 Peptide Receptor Radionuclide Therapy for Progressive and Metastatic Neuroendocrine Tumors: Analysis of Efficacy in 1000 Patients from a Single Center
Introduction: Peptide receptor radionuclide therapy (PRRT) is beneficial in well-differentiated neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Prof. Richard P Baum
Keywords: PRRT
#1125 Efficacy of PRRT in Metastatic Neuroendocrine Tumors; A Retrospective Large Single Institutional Study
Introduction: PRRT is a well-documented and well-established treatment for metastatic neuroendocrine tumours. However retrospective studies detailing the efficacy of PRRT are lacking.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Haamid Jan
Authors: Jan H, Wyld D, Burge M, ...